Figure 1. Daily plasma glucose profile as well as fasting and 2-h postprandial levels of C-peptide and glucagon before the administration of once-weekly dulaglutide (a) and after switching from vildagliptin to dulaglutide (b).
| Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc |
| Journal website http://www.jofem.org |
Case Report
Volume 8, Number 1, February 2018, pages 6-9
Improved Glycemic Control due to Reduction in Glucagon Levels by the Administration of Once-Weekly Dulaglutide in a Non-Obese Patient With Type 2 Diabetes
Figure
Table
| BMI: body mass index; WC: waist circumference; AST: aspartate aminotransferase; ALT: alanine aminotransferase; BUN: blood urea nitrogen; Cre: creatinine; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; GA: glycoalbumin; U-ACR: urinary albumin creatinine ratio. | |
| Age (years) | 67 |
| Height (cm) | 156.2 |
| Weight (kg) | 50 |
| BMI (kg/m2) | 20.5 |
| WC (cm) | 82.5 |
| Duration of diabetes (years) | 15 |
| AST (U/L) | 55 |
| ALT (U/L) | 60 |
| BUN (mg/dL) | 7.3 |
| Cre (mg/dL) | 0.48 |
| eGFR (ml/min/1.73 m2) | 95.7 |
| Plasma glucose (mg/dL) | 206 |
| HbA1c (%) | 11.1 |
| GA (%) | 29.6 |
| U-ACR (mg/gCre) | 0 |